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affects the sensitivity of osteosarcoma to cisplatin
by regulating the expression and/or activity of
Caspase family
Lei Wang1, Fangchun Jin1, An Qin1, Yongqiang Hao1*, Yufeng Dong2, Shengfang Ge3 and Kerong Dai1Abstract
Background: The introduction of cisplatin has improved the long-term survival rate in osteosarcoma patients. However,
some patients are intrinsically resistant to cisplatin. This study reported that the activation of Notch1 is positively
correlated with cisplatin sensitivity, evidenced by both clinical and in vitro data.
Results: In this study, a total 8 osteosarcoma specimens were enrolled and divided into two groups according to
their cancer chemotherapeutic drugs sensitivity examination results. The relationship between Notch1 expression
and cisplatin sensitivity of osteosarcoma patients was detected by immunohistochemistry and semi-quantitative
analysis. Subsequently, two typical osteosarcoma cell lines, Saos-2 and MG63, were selected to study the changes
of cisplatin sensitivity by up-regulating (NICD1 plasmid transfeciton) or decreasing (gamma-secretase complex
inhibitor DAPT) the activation state of Notch1 signaling pathway. Our results showed a significant correlation
between the expression of Notch1 and cisplatin sensitivity in patient specimens. In vitro, Saos-2 with higher
expression of Notch1 had significantly better cisplatin sensitivity than MG63 whose Notch1 level was relatively
lower. By targeting regulation in vitro, the cisplatin sensitivity of Saos-2 and MG63 had significantly increased after
the activation of Notch1 signaling pathway, and vice versa. Further mechanism investigation revealed that activation/
inhibition of Notch1 sensitized/desensitized cisplatin-induced apoptosis, which probably depended on the changes in
the activity of Caspase family, including Caspase 3, Caspase 8 and Caspase 9 in these cells.
Conclusions: Our data clearly demonstrated that Notch1 is critical for cisplatin sensitivity in osteosarcoma. It can be
used as a molecular marker and regulator for cisplatin sensitivity in osteosarcoma patients.
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Osteosarcoma is the most common primary malignant
bone tumor. It has a typical age related incidence rate,
with a first peak occurring in the second decade (3.1-4.2
per 1,000,000 person years) and a second peak occurring
in patients older than sixty (3.3-4.6 per 1,000,000 person
years) [1-3]. Current treatments for osteosarcoma include
combined approaches of surgery dissection and systemic
chemotherapy. It is undeniable that the introduction of* Correspondence: hyq_9hospital@hotmail.com
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unless otherwise stated.adjuvant and neoadjuvant chemotherapies has im-
proved the long-term survival rate impressively [4-6].
For example, the use of cisplatin has been proved to be
a useful chemotherapeutic method for preoperative in-
duction therapy for osteosarcoma. Good responders to
preoperative cisplatin chemotherapy showed a better
survival rate [7]. Besides, it was also well summarized
that the inclusion of cisplatin had better outcome for
high grade osteosarcoma [8].
Cisplatin is an effective antitumor agent with a wide
spectrum of activity against human solid tumors [9-13].
Generally, it can form bivalent adducts with nucleophilic
sites on purines in DNA, yield predominantly DNAtd. This is an Open Access article distributed under the terms of the Creative
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and thus exert antitumor effects. However, while some
common tumors are sensitive to cisplatin treatment,
others are instrinsically resistant to cisplatin [15], leading
to failure in the curative therapy. However, the under-
lying mechanisms of cisplatin resistance are still unclear.
Identifying molecules that contribute to cisplatin resistance
would be necessary and significant for the optimization of
curative effects.
The Notch signaling pathway is an evolutionarily con-
served ligand-receptor signaling system that regulates
cell proliferation, survival, apoptosis and differentiation
[16,17]. Four Notch receptors have been identified in
mammals, namely Notch1-4. Upon the binding of a lig-
and (jagged 1, jagged 2, delta-like 1 or delta-like 4) to
the cell surface Notch receptors (Notch1-4), the Notch
intracellular domain (NICD) will be cleaved by the
gamma-secretase complex and translocated into the nu-
cleus to induce the expression of downstream targeting
genes including Hes1, Hes5, Hes7, Hey1, Hey2 and HeyL
etc. [18]. Dysfunction of Notch signaling pathway may
lead to anomalous differentiation or undifferentiation,
ultimately causing these cells toward malignant trans-
formation. Indeed, many observations suggested that al-
terations in Notch signaling are associated with many
human cancers [19-23]. In addition, Notch signaling path-
way is also involved in chemotherapy drug-resistance. For
instance, Notch1 plays an important role in the mecha-
nisms of cisplatin resistance in several malignant tumors,
such as head and neck squamous cell tumors, colorectal
tumors and ovarian cancer [24]. However, the roles of
Notch1 signaling in osteosarcoma and chemotherapy re-
sponse have not been elucidated yet. Therefore, this study
aims to determine the roles of Notch1 signaling pathway




Conventional osteosarcoma patients involved in this
study were hospitalized in the Department of Orthopedic
Surgery of the Ninth People’s Hospital of Shanghai, China
between September 2010 and March 2012. All patients
who enrolled provided informed consent in accordance
with our institution’s regulatory requirements, and we
conducted the study according to guidelines of the ethic
committee of Ninth People's Hospital of Shanghai Jiaotong
University.
In all cases, diagnosis of conventional osteosarcoma was
established by clinical characteristics, radiological findings
and pathological examination. Participants were randomly
selected from our sample library, included seven patients
(six males, one female) with median age of 31.6 years
(range: 17–58 years). However, it is worthwhile to explainthat one of these patients suffered a tumor recurrence
after surgery operation within one year. Therefore, we
have a total of eight histological specimens: sample
001–008 (sample 003 and sample 005 were both from
the recurrence patient) which were all obtained after le-
sion excision. Then according to the inhibition rate of
cisplatin in the tumor susceptibility test results, the
histological specimens of these patients were divided
into two groups: cisplatin sensitive group (cisplatin sensi-
tivity 50%-90%) and cisplatin insensitive group (cisplatin
sensitivity 0-30%). The two groups had no significant
difference in composition regarding age or sex (P > 0. 05).
Cell culture
Human osteosarcoma cell lines, Saos-2 and MG63 cells
were purchased from the Shanghai Institute of Bio-
chemistry and Cell Biology (Shanghai, China). They
were authenticated using DNA fingerprinting (variable
number of tandem repeats), confirming that no cross-
contamination occurred during this study. The cell
lines were used within 6 months of resuscitation. Cells
were grown in α-MEM (GIBCO, Grand Island, NY,
USA) supplemented with 10% FBS (Hy-clone, Tauranga,
New Zealand) and antibiotics (penicillin 100 U/ml,
streptomycin 100 lg/ml; Hyclone, Logan, UT,USA) in
37°C humidified atmosphere with 5% CO2.
Immunohistochemistry and immunocytochemistry
Immunohistochemical staining for Notch1 and HES1
were performed on 5 μm thick formalin-fixed paraffin
embedded sections. Deparafinization and rehydration
were performed in xylene and ethanol solutions (redu-
cing concentration 95%-70%). Sections were incubated
in H2O2 solution (3% H2O2 in PBS buffer) for 30 minutes
to block endogenous peroxydase. Antigen retrieval were
performed in procedure with the retrieval buffer (PH =
9.0, TRIS 20 mmol/L, EDTA 0.05 mmol/L, 0.05% Tween
20) in 99°C bath for 20 minutes. Sections were then in-
cubated with the primary antibody: anti-HES1 (diluted
1:250, Epitomics, USA) and anti-Notch1 (diluted 1:50,
Epitomics, USA) at 4°C overnight. After rinsing with the
PBS buffer, the secondary antibody (MaxVision TM
HRP-Polymer anti-Rabbit IHC Kit, Maixin.Bio, China)
was applied for 15 minutes at room temperature (RT).
DAB (Maixin.Bio, China) solution was used for chromogen.
At last, the Sections were counterstained with Hematoxylin
(Sigma) to identify nuclei. Immunohistochemistry with
the secondary antibody alone without primary antibody
was carried out as a control. The images were acquired
using a microscope (Leica DM 4000B) with BioQuant
OSTEO II software (BioQuant Image AnalysisCorporation,
Nashville, TN).
Immunocytochemistry for Notch1 of Saos-2 and MG63
cells were performed in 6-well plate. Supernatant was
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three times. Then 0.2% Triton X-100 was added to
penetrate cytomembrane for 5 minutes and 5% BSA
was used for 30 minutes to block unspecific binding of
the antibodies. Subsequently, sections were incubated
with the primary antibody against Notch1 (diluted
1:100, Epitomics, USA) at 4°C overnight. After washing
three times with PBS buffer, the cells were incubated
with anti-rabbit Alexa594 (1:500, Molecular Probes,
USA) for 30 minutes. DAPI (300 nM, Molecular Probes,
USA) was used to counterstain the nuclei. At last, the im-
ages were acquired using an inverted fluorescence micro-
scope (IX71, Olympus, Japan) with DP Controller software.
Activation and inhibition of Notch1 signaling pathway of
Saos-2 and MG63 cells
For the activation of Notch1 signaling pathway of Saos-2
and MG63 cells, the Notch1 intracellular domain (NICD-
1) plasmid which was cloned 2.4 kb NICD-1 fragment to
pcDNA3.1 vector using forward primer: 5′-CACC ATG
GTG CTG CTG TCC CGC AA GCGCC and reverse pri-
mer: 5′- TGC TTT AAA TGC CAC AGG AAT GTG GG
was used to transfect into the two cell lines according to
the protocols of Lipofectamine™ Reagent (Invitrogen,
USA). Three days later, we detected the expression of
HES1 mRNA, the main downstream aim target of Notch
signaling pathway, as the indication of the activation of
Notch1 signaling pathway by the plasmid. Subsequently,
these cells were seeded into 96-well plate for the follow-
up studies.
LY-374973, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester (DAPT) (ENZO Life Sciences,
USA), the inhibitor of γ-secretase complex in Notch sig-
naling pathway, was used to non-specific inhibit the
Notch1 signaling pathway of Saos-2 and MG63 cells. The
cells were incubated in DAPT (100 μmol/L) in the 6-well/
96-well plates for 24 hours. And then DAPT was removed
and the cells were washed with fresh medium twice before
cisplatin added.
Real-time PCR
Total RNA was isolated by using the AxyPrepTM Multi-
source Total RNA Miniprepkit (Axygen, USA). An equiva-
lent amount of RNA was converted into complementary
DNA (cDNA) with PrimeScript™ RT reagent Kit (Takara,
Japan). Subsequently, Real-time PCR was performed using
an ABI 7500 Sequencing Detection System and SYBR®Pre-
mix Ex Taq (Takara, Japan). All of the procedures were per-
formed according to the manufacturer’s protocols. Cycling
condition was as follows: 40 cycles at 95°C for 5 seconds
and 60°C for 34 seconds. The primer sequences are, for hu-
man Notch1: forward 5′-GGA GGC ATC CTA CCC TTT
TC-3′, and reverse 5′-TGT GTT GCT GGA GCA TCT
TC-3′; for human HES1: forward 5′-CTC TCT TCC CTCCGG ACT CT-3′ and reverse 5′-AGG CGC AAT CCA
ATA TGA AC-3′; for human Caspase3: forward 5′-TTT
TTC AGA GGG GAT CGT TG-3′ and reverse 5′-CGG
CCT CCA CTG GTA TTT TA-3′; for human Caspase8:
forward 5′-TGC AGG GTC TCA CTC TGT TG-3′ and
reverse 5′-CAA AAA TCA GCC ATG TGT GG-3′; for
human Caspase9: forward 5′-CTA GTT TGC CCA CAC
CCA GT-3′; and for human GAPDH: forward 5′-CCT
GCA CCA CCA ACT GCT TA-3′ and reverse 5′-AGG
CCA TGC CAG TGA GCT T-3′. The comparative 2-
ΔΔCT method was used to calculate the relative ex-
pression level of each target gene with GAPDH as the
housekeeping gene.
Western blot
At the end of incubation, cells were washed with PBS
and dissolved in lysis buffer containing protease inhibi-
tor. Equal amount of proteins in cell homogenates were
subjected to 10% SDS–PAGE and transferred to 0.22 μm
PVDF membranes. The membranes were blocked with
5% free fat milk at room temperature for 1 h and then
incubated with primary antibodies (all in accordance with
1:1,000 dilution), including rabbit monoclonal anti-Notch1
intracellular domain, rabbit monoclonal anti- Pro-Caspase3/
cleaved Caspase3, rabbit monoclonal anti-Caspase8 and
mouse monoclonal Pro-Caspase9/cleaved Caspase9 (all
were purchased from Cell Signaling Technology, USA),
overnight at 4°C, after 3 washes in TBST, the mem-
branes were incubated with anti-rabbit or anti-mouse
IgG for 1 h at room temperature. After washing, the
membranes were incubated with enhanced chemilu-
minescence system (ECL) detection kit (Amersham Life
Science, Little Chalfont, UK). Positive immunoreactive
bands were quantified densitometrically, normalized by
GAPDH.
Remaining cells test after treated with cisplatin by
CCK-8 assay
A cell count kit-8 (CCK-8, Dojindo, Japan) was employed
in this experiment to quantitatively evaluate the remaining
cells viability after Saos-2 and MG63 cells whose
Notch1 signaling pathway was activated or inhibited
were treated with cisplatin (10 μg/ml, 5 μg/ml and
2.5 μg/ml). Cisplatin application concentration was cal-
culated according to the clinical treatment program
(20 mg/m2 ≈ 5 μg/ml). Approximately 7 × 103 cells were
seeded on each film placed in the 96-well plates. The
culture medium was removed and the cells were
washed with PBS before CCK-8 examination. Subse-
quently, 100 μl α-MEM medium and 10 μl CCK-8 solu-
tion were added to each sample, followed by incubation
at 37°C for 2.5 hours. The optical density (OD) at
450 nm was determined using a microplate reader
(BIO-TEK, USA). At last, all the CCK8 results in our
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the ratio of remaining cell and the proliferation rate:Ratio of remaining cell relative sensitivity to cisplatinð Þ
¼ the 24h=36h absorption value of cisplatin treatment groupthe 24h=36h absorption value of cisplatin untreatment control group ;
Proliferation rate
¼ the 24=36h absorption value of cisplatin untreatment groupthe 0h absorption value of cisplatin untreatment group :Analysis of apoptosis
Cells were seeded at 200,000 cells per well in six-well
plates. NICD-1 plasmid transfection cells were harvested
at 24 hours after 5 μg/ml cisplatin treatment and 36 hours
for DAPT treatment cells. Cells were washed twice with
cold PBS and then re-centrifuged the washed cells, dis-
carded the supernatants and resuspended the cells in 1X
annexin-binding buffer. Early apoptosis was detected by
staining with Alexa Fluor® 488 annexin V and Propidium
iodide labeling using the Vybrant® Apoptosis Assay Kit #2
(Invitrogen, USA). FACS was performed using a FACScan
flowcytometer (Beckman-Altra, USA). Data were acquired
using CELL Quest software.
Statistics analysis
Each sample was analysed in triplicate, and experiments
were repeated three times. Mean, standard deviation
(SD), and P values base on the 2-tailed t test were calcu-
lated with Excel X (Microsoft). Differences were consid-
ered significant at P < 0.05.
Results
Osteosarcoma patients with higher Notch1 expression are
more sensitive to cisplatin treatment
Osteosarcoma cells from different patients exhibited dif-
ferent response to cisplatin treatment. According to the
inhibition rate of cisplatin and carboplatin on tumor
cells from different patients, all the osteosarcoma pa-
tients were divided into two groups: cisplatin sensitive
group (samples 001–004) and cisplatin insensitive group
(samples 005–008). Approximately 63.88 ± 14.57% of the
osteosacoma cells respond to cisplatin treatment in the
sensitive group while 6.88 ± 6.33% respond to cisplatin
treatment in the insensitive group (Additional file 1:
Table S1). Then, the expression profile of Notch1 and
HES1 were analyzed by immunohistochemical staining
(Figure 1A and B). As shown in Figure 1, intense immu-
noreactivity of Notch1 and HES1 was observed in cis-
platin sensitive patients (samples 001–004). On the
contrary, low expression of Notch1 and HES1 was ob-
served in specimens from cisplatin insensitive patients
(samples 005–008). It was worth noting that sample 003
and sample 005 were from the same patient at different
stage. Sample 003 was obtained from primary osteosarcoma
while sample 005 was taken from recurrent osteosarcoma.Interestingly, sample from the primary osteosarcoma
were sensitive to cisplatin treatment (inhibition rate:
54.28%) with higher Notch1 and HES1 expression. In
contrast, sample from the recurrent osteosarcoma were
insensitive (inhibition rate: 0.00%) to cisplatin treat-
ment with low Notch1 and HES1 expression. Together,
these data suggested that cisplatin sensitivity was posi-
tively correlated with Notch1 expression.
Osteosarcoma cell line with higher Notch1 expression is
more sensitive to cisplatin treatment
In order to verify the positive relationship between the
expression of Notch1 and cisplatin sensitivity in osteo-
sarcoma, two osteosarcoma cell lines, Saos-2 and MG63,
were analyzed in vitro. Both two cell lines are the most
commonly used osteosarcoma cell lines. They have sub-
stantially similar cell morphology, cell cycle and culture
conditions, which will make it easy for us to unify the
cisplatin dose and time points in subsequent experi-
ments. Initial realtime PCR revealed Notch1 expression
was approximately 7 fold higher in Saos-2 cells than
MG63 cells (Figure 2A). This result was further con-
firmed by Western Blot and immunocytochemistry,
showing significantly higher Notch1 expression in Saos-
2 cells (Figure 2B and C). Both Saos-2 and MG63 cell
lines showed a dose and time dependent response to cis-
platin treatment (10 μg/ml, 5 μg/ml, and 2.5 μg/ml) after
12 h, 24 h, 36 h and 48 h (Figure 2D). Inteterstingly,
Saos-2 cells were more sensitive to cisplatin treatment
than MG63 cells, as evidenced by significant lower cell
viability in the Saos-2 group after cisplatin treatment
(Figure 2E). Collectively, these data indicated that Saos-2
with higher Notch1 expression was more sensitive to
cisplatin treatment while MG63 with lower Notch1 ex-
pression was relatively insensitive to cisplatin treatment.
Activation of Notch1 signaling pathway sensitizes
osteosarcoma cell lines to cisplatin treatment
The activation of notch intracellular domain (NICD) is a
key step for Notch signaling pathway. Thus, the NICD-1
plasmid was transfected into MG63 or Saos-2 cells to
activate their Notch1 signaling pathway. The activation
of Notch1 signaling was confirmed by the expression of
targeting gene HES1 which increased approximately 50-
fold and 5.8-fold in MG63 and Saos-2 cells respectively
(Figure 3A and B). Subsequently, the activated cell lines
were treated with different concentrations of cisplatin
(10 μg/ml, 5 μg/ml and 2.5 μg/ml) for 24 hours. Interest-
ingly, both activated MG63 and Saos-2 exhibited signifi-
cantly increased sensitivity to cisplatin compare to their
control groups (Figure 3C and D). More than 80% of the
activated MG63 cells (MG63-NICD-1) respond to cis-
platin at 10 μg/ml while only about 50% of the MG63
cells are sensitive to cisplatin treatment at the same
Figure 1 Immunohistochemistry showed the expression of Notch1 and HES1 in cisplatin sensitive group and insensitive group. The
histopathology revealed the irregular nuclei, some spindle cells, and even destroyed bone (A and B, Column 1). Immunohistochemical examination of
Notch1 and HES1 were carried out in different patients. There is significant more expression of Notch1 and HES1 in cisplatin sensitive patients than
cisplatin insensitive patients in gross appearance (A and B, Column 2 and 3) and semi-quantitative scatter plot below (C and D). Column 4 in A and B
was the negative control with the secondary antibody alone without primary antibody. (**P < 0.01).
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lines. Additionally, in order to exclude the influence of
the plasmid on cell proliferation, the 24 h proliferation
rate was also examined in the two cell lines with pure
plasmid transfection. There was no significantly differ-
ence between the NICD-1 transfected group and control
group in MG63. Saos-2 with NICD-1 transfection showed
a higher proliferation rate (Additional file 2: Figure S1).
Together, these results suggested that the activation ofNotch1 signaling pathway sensitized osteosarcoma cells to
cisplatin treatment.
Inhibition of Notch1 signaling pathway desensitizes
osteosarcoma cell lines to cisplatin treatment
In order to further confirm our previous results, DAPT,
the inhibitor of γ-secretase complex in Notch signaling
pathway, was used to inhibit Notch1 signaling pathway.
After treatment with DAPT for 24 hours, the expression
Figure 2 The expression of Notch1 in MG63 and Saos-2 cell lines and their sensitivity to cisplatin. Real-time PCR revealed that Saos-2 cells
had approximately 7 fold higher Notch1 expression than MG63 cells (A). We further carried out Western Blot and immunocytochemistry to determine
the protein expression in MG63 and Saos-2. The level of Notch1 in Saos-2 is significantly higher than MG63 (error bar means s.d.) (B and C). Both two cell
lines showed dose and time dependent response to cisplatin (D). Saos-2 performed significantly higher sensitivity to cisplatin (E). (*P < 0.05, **P < 0.01).
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validate the inhibition efficiency of DAPT. As shown in
Figure 4, HES1 was suppressed approximately 50% in
MG63 and 40% in Saos-2 after the inhibition of Notch1signaling pathway (Figure 4A and B). Different concen-
trations of cisplatin (10 μg/ml, 5 μg/ml and 2.5 μg/ml)
were used to treat the inhibited MG63 and Saos-2 cells.
Consistent with previous findings, we found that there
Figure 3 Activation of Notch1 signaling pathway increased the sensitivity of MG63 and Saos-2 to cisplatin. Real-time PCR indicated that
HES1 mRNA in MG63 and Saos-2 had significantly more expression after NICD-1 plasmid transfection (A and B). The sensitivity of MG63 and
Saos-2 to cisplatin has significantly increased after the activation of Notch1 signaling pathway (C and D). (*P < 0.05; **P < 0.01).
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than the control group, indicating that MG63 and
Saos-2 became relatively insensitive to cisplatin after
the inhibition of Notch1 signaling pathway (Figure 4C
and D). Additionally, in order to exclude the influence
of DAPT on the results above, the proliferation rates were
also examined in the two cell lines with DAPT treatment
only. The result revealed that two cell lines showed no sig-
nificant change in proliferation in the follow-up 36 hours
after DAPT being removed (Additional file 3: Figure S2).
Taken together, we demonstrated that suppression of
Notch1 signaling pathway desensitized osteosarcoma cells
to cisplatin treatment.
After targeted regulation of Notch1 signaling pathway,
osteosarcoma cells apoptosis changes under the
cisplatin effect
To better understand the effect of Notch1 signaling
pathway on cisplatin-sensitivity in osteosarcoma, we ex-
amined the apoptosis rate induced by cisplatin. Our flow
cytometry results showed that cisplatin induced approxi-
mately more than one fold apoptosis in NICD-1 plasmid
activated cells (MG63 13.21% and Saos-2 8.09%) than
control cells (MG63 5.45% and Saos-2 3.99%) after24 hour cisplatin treatment (Figure 5A and B). In contrast,
cisplatin induced apoptosis in 18.37% of DAPT inhibited
MG63 cells and 11.40% of DAPT inhibited Saos-2 cells,
which was much less than their control group (37.97% of
MG63 and 19.26% of Saos-2) (Figure 5C and D). Collect-
ively, these results indicated that Notch1 activation might
enhance cisplatin induced osteosarcoma cell apoptosis.
Inhibition of Notch1 signaling pathway decreases the
expression and/or activity of Caspase3, Caspase8 and
Caspase9 in osteosarcoma cells even under the effect
of cisplatin
Cell apoptosis is a complex process that involves a variety
of regulatory mechanisms. However, it is generally appre-
ciated that Caspase family plays a crucial role in the regu-
lation of cell apoptosis. Therefore, the expression and
activity of Caspase3, one of the most important apoptosis
executioners, Caspase8 and Caspase9, the most critical
initiators of Caspase3, were detected in this part. Initially,
realtime PCR revealed that Caspase3, Caspase8 and
Caspase9 gene expression displayed different degrees of
reduction with a simple DAPT treatment for 24 hours
in MG63 and Saos-2 cells (Figure 6A and C). However,
the expression of each Caspase gene was further
Figure 4 Inhibition of Notch1 signaling pathway decreased the sensitivity of MG63 and Saos-2 to cisplatin. Real-time PCR indicated that
HES1 mRNA in MG63 and Saos-2 had significantly less expression after DAPT treatment (A and B). The sensitivity of MG63 and Saos-2 to cisplatin
has significantly decreased after the inhibition of Notch1 signaling pathway (C and D). (*P < 0.05; **P < 0.01).
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to DMSO group after a subsequent treatment with cis-
platin for 12 hours (Figure 6B and D). Then, we simul-
taneously detected the protein expression of Caspase3
(Pro-Casp3), active Caspase3 (Cleaved-Casp3), Cas-
pase8 (Casp8), Caspase9 (Pro-Casp9) and active Cas-
pase9 (Cleaved-Casp9) in MG63 and Saos-2. Changes
in the expression of Caspase3, Caspase8 and Caspase9
were broadly consistent with the genes, but they were
still a little different. After treatment with DAPT for
24 hours with or without cisplatin reprocessing, the
protein expressions of Pro-Casp3 and Cleaved-Casp3
which were likely to be the critical molecules affected
by Notch1 signaling pathway were both significantly
lower than the control group in MG63 and Saos-2 cells
(Figure 6E-H). However, although the expression of the
other indicators including Casp8, Pro-Casp9 and Cleaved-
Casp9 didn’t show an obvious difference observed by
naked eye between the two groups when the cells were
only treated with DMSO or DAPT, a statistically differ-
ence that the expression levels of these proteins in DAPT
group were significantly lower than it in DMSO group did
exist. And then such slight difference magnified after the
cisplatin treatment for 12 hours (Figure 6E-H). Therefore,we concluded that inhibition of Notch1 signaling pathway
even with cisplatin treatment in osteosarcoma cells might
directly or indirectly decrease the expression and/or activ-
ity of Caspase family proteins, generally leading to re-
duced sensitivity to cisplatin at last.
Discussion
The use of multiagent, intensive chemotherapy has proved
to be a major development in osteosarcoma treatment. It
has dramatically changed osteosarcoma from a malignancy
with a modest survival rate to one in which at least two
thirds of patients could be cured [25,26]. Cisplatin is one of
the most common first-line chemotherapy drugs for osteo-
sarcoma because of its DNA cross-linking activity [27].
However, not all osteosarcoma patients are sensitive to cis-
platin treatment [28]. Therefore, correctly distinguishing
patient response to cisplatin treatment would allow sensi-
tive patients to benefit from chemotherapy and avoid non-
responsive patients suffering from unnecessary side effects.
In our study, we for the first time identified that the
expression of Notch1 and HES1 in osteosarcoma speci-
mens were positively correlated with cisplatin sensitivity
in osteosarcoma patients. In vitro study confirmed this
finding that osteosarcoma cell line Saos-2 with higher
Figure 5 Notch1 signaling pathway regulated cisplatin sensitivity of MG63 and Saos-2 via changing the apoptosis effect. After overexpression
of NICD-1, cisplatin could induce more apoptosis in MG63 and Saos2 cells than their control group (A and B). When Notch1 signaling pathway
was inhibited by DAPT, cisplatin induced fewer apoptosis cells in both osteosarcoma cell lines (C and D). (*P < 0.05; **P < 0.01).
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Figure 6 Inhibition of Notch1 signaling pathway decreased the expression and/or activity of Caspase3, Caspase8 and Caspase9. In the
two cell lines, realtime PCR indicated that the gene expression of Caspase3, Caspase8 and Caspase9 were reduced to some extent after a simple
DAPT treatment for 24 hours. Further reduction was observed with cisplatin subsequent treatment for 12 hours (A, B, C and D). Simultaneously,
western blot was carried out to detect the protein expression of Pro-Casp3, Cleaved-Casp3, Casp8, Pro-Casp9 and Cleaved-Casp9. The expression
of these several proteins significantly decreased after DAPT treatment in MG63 and Saos-2 cells. Further, such difference between two groups
could be obviously magnified after cisplatin treatment (E, F, G and H). (*P < 0.05; **P < 0.01).
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MG63 with lower Notch1 expression. Subsequently, we
consolidated such discovery by activating or suppressing
Notch1 signaling pathway further. Activation of Notch1
signaling pathway significantly sensitized osteosarcoma
cells to cisplatin treatment while inhibition of Notch1
signaling pathway desensitized these cells to cisplatin.
We further revealed that changing the activity of Notch1
signaling pathway was able to affect the cell apoptosis to
regulate the sensitivity of osteosarcoma to cisplatin, which
might be mainly caused by the expression and/or activity
changes of Caspase family proteins. As was shown inFigure 6, inhibition of Notch1 signaling pathway could
significantly decrease the amount of Caspase family
proteins, especially Pro-Caspase 3 and Cleaved-Caspase 3,
after cisplatin treatment. Therefore, on the view of macro-
scopic, osteosarcoma cells showed decreased apoptosis
and insensitivity to cisplatin. On the contrary, we specu-
lated that activation of Notch1 signaling pathway would
have the opposite effect on the expression and/or activity
of Caspase family proteins, which could lead osteosar-
coma more sensitive to cisplatin. Overall, our study
comprehensively revealed that the expression of Notch1
was positively correlated with cisplatin sensitivity in
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lecular marker for predicting and even regulating the cis-
platin sensitivity in osteosarcoma patients.
The highly conserved Notch signaling pathway plays
important roles in controlling a wide variety of cell fate
decisions and governs numerous developmental pro-
cesses which affect the development and function of
many organs. Notch signaling pathway has a consan-
guineous relationship with osteosarcoma in its patho-
genesis, development, invasion, and metastasis in recent
studies [23,29,30]. However, the influence of Notch sig-
naling pathway on osteosarcoma chemotherapy sensitiv-
ity has hardly been reported before. Previous studies
have reported activation of Notch1 signaling pathway
was negatively related to cisplatin sensitivity in malig-
nancies of head and neck squamous cell tumors [31,32].
Opposite to these findings, we reported that activation
of Notch signaling pathway was positively related with cis-
platin sensitivity in osteosarcoma. Notch can have either
an oncogenic [19-23] or a tumour-suppressor [33,34] role.
Thus, this might be epitomized by its different contribu-
tions to cancers in different tumor types. Therefore, we
consider that the opposite findings from our study and
previous studies may due to the different effects of Notch1
in different tumors. Osteosarcoma is a kind of malignancy
derived from mesenchymal tissue. Therefore, we might
also be able to comprehend the above results by drawing
lessons from the effect of Notch signaling pathway in bone
marrow mesenchymal stem cells (MSCs). Some researches
showed that Notch signaling pathway undertook an im-
portant regulation action in the proliferation and differen-
tiation of MSCs: activation of Notch signaling pathway
could obviously inhibit the process of osteogenic and
chondrogenic differentiation [35-38]. Thus, Notch signal-
ing pathway would keep them in an undifferentiated or
poorly differentiated state. Similarly, we would speculate
that the activation of Notch1 signaling pathway may retain
osteosarcoma cells in an undifferentiated stage, in which
cell division and DNA replication process may be more
frequent. When osteosarcoma cells are treated with
chemotherapy drugs whose target is DNA, DNA damage
and replication errors would be more likely to occur in
this case, directly leading to the initiation of cell apoptosis.
Indeed, poorly differentiated osteosarcoma cells tend to be
more sensitive to chemotherapy in clinical. On the con-
trary, well-differentiated tumors are always insensitive to
chemotherapy, which might be also the deeper reason for
the phenomenon observed in our present study.
Cisplatin, one of the most common anti-neoplastic
drugs, is always able to bring better prognosis for sensi-
tive patients. Our study proved that Notch1 signaling
pathway whose activity changes might directly or indir-
ectly affect the expression and activity of Caspase family
proteins was also a possible key regulator for cellapoptosis induced by cisplatin in osteosarcoma. That is
to say, Notch1 signaling pathway possibly plays a vital
role in the anti-neoplastic effect of drugs with potential
apoptosis-inducing ability. However, the following points
are still to be resovled about our research: 1) more patients
samples should be collected to further verify the relation-
ship between Notch1 signaling pathway and cisplatin sensi-
tivity; 2) the intermediate molecular mechanisms on how
Notch1 changing the expression and activity of Caspase
family proteins should be better clarified; 3) more chemo-
therapy drugs with potential apoptosis-inducing ability
should be involved to try to reveal the universal law.
Conclusions
Our findings showed that Notch1 signaling pathway had a
positive correlation with cisplatin sensitivity in osteosar-
coma. This novel finding adds to the understanding of
osteosarcoma chemotherapy sensitivity. Notch1 signaling
pathway can be used as a molecular marker for cisplatin
sensitivity in osteosarcoma patients.
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On the contrary, it could significantly promote the proliferation of Saos-2.
Additional file 3: Figure S2. Cells were only treated with DAPT and
without cisplatin showed no obvious influence on the proliferation of
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